Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar;32(3):295-297.
doi: 10.1016/j.annonc.2020.11.018. Epub 2020 Dec 8.

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy

M Sznol  1 , I Melero  2
Affiliations
Free article
Editorial

Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy

M Sznol et al. Ann Oncol. 2021 Mar.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure IM: Advisor: Bristol-Myers Squibb (BMS), Roche, F-STAR, Boehringer Ingelheim, Biontech, Merck, Serono, Numab, Servier, Alligator, Pieris, AstraZeneca. Grants: Roche, BMS, Biontech, Alligator. Speaker honoraria. AstraZeneca, Merck Sharp & Dohme, BMS. MS: Consulting: Idera, Regeneron, Apexigen, Alligator, Verastem, Agenus, Rubius, Bristol-Myers, Genentech-Roche, Boston Pharmaceuticals, Servier, Adaptimmune, Immunocore, Dragonfly, Pierre-Fabre, Molecular Partners, Boehringer Ingelheim, Innate Pharma, Nektar, Pieris, Numab, Abbvie, Zelluna, Seattle Genetics, Genocea, GI Innovation, Chugai-Roche, Biontech, Lilly, Modulate Therapeutics, Array, AstraZeneca, Genmab. Stock Options: Evolveimmune, Nextcure, Torque-Repertoire, Adaptive Biotechnologies, Actym, Amphivena. Stock Ownership: Glaxo-Smith Kline, Johnson and Johnson.

Comment on

LinkOut - more resources